TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03214497

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Protector
Description: All patients which are assigned to the Protector are studied with this laryngeal mask

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Supreme
Description: All patients which are assigned to the Supreme are studied with this laryngeal mask
Study: NCT02053350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alanyl-glutamine
Description: Alanyl-glutamine, 44g, taken by mouth daily for 10 days
Study: NCT00392561

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Selenium
Description: 200 ug Selenium daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Selenium
Description: 200 ug Selenium daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin E
Description: 100 mg Vitamin E daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin E
Description: 100 mg Vitamin E daily
Study: NCT03010202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Comparing maintenance dose of 500mg Rituximab at week 1 and week 24 to Placebo
Study: NCT04109378

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical procedures( conventional laparoscopic and NOSE technique) for the treatment of colorectal DIE
Description: For conventional laparoscopic and NOSE techniques a 4-port approach is used. The rectum is skeletonized. The distal rectum is closed using an endoscopic linear stapler. The mobilized rectum with the specimen is retrieved through a small suprapubic incision. The anvil of a conventional circular stapler is introduced in the proximal colon after placement of a purse string suture. A circular stapled colorectal anastomosis is fired. In case of NOSE, both the proximal sigmoid colon and the proximal rectum are tied off laparoscopically with a nonabsorbable suture. A transverse colotomy is performed in healthy tissue using a harmonic scalpel to deliver the anvil from a circular stapler introduced through the anus. The specimen is extracted transrectally in a specimen retrieval bag. Proximal part of the anastomosis is completed by suturing the anvil in place with a laparoscopic suture. The distal rectum is closed using a linear stapler. End-to-end anastomosis is made using the circular stapler

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical procedures( conventional laparoscopic and NOSE technique) for the treatment of colorectal DIE
Description: For conventional laparoscopic and NOSE techniques a 4-port approach is used. The rectum is skeletonized. The distal rectum is closed using an endoscopic linear stapler. The mobilized rectum with the specimen is retrieved through a small suprapubic incision. The anvil of a conventional circular stapler is introduced in the proximal colon after placement of a purse string suture. A circular stapled colorectal anastomosis is fired. In case of NOSE, both the proximal sigmoid colon and the proximal rectum are tied off laparoscopically with a nonabsorbable suture. A transverse colotomy is performed in healthy tissue using a harmonic scalpel to deliver the anvil from a circular stapler introduced through the anus. The specimen is extracted transrectally in a specimen retrieval bag. Proximal part of the anastomosis is completed by suturing the anvil in place with a laparoscopic suture. The distal rectum is closed using a linear stapler. End-to-end anastomosis is made using the circular stapler
Study: NCT03946943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Once a day dosing of anlotinib alone for the first 7 days, Anlotinib ( 12mg, QD, PO, d1-14, 21 days per cycle), take once when limosis in the morning. If patients cannot suffer from AEs, they can get declined dosage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab 240mg shall be administered via intravenous (IV) infusion, once every 21 days, on day 8 and day 29 of the first cycle, and days 1 and 22 of the following cycles.
Study: NCT01145703

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: RDA Vitamin D3 only
Description: 800 IU of Vitamin D3 daily for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D2/3 Repletion only
Description: Vitamin D repletion with 50,000 IU of Vitamin D2/3 up to 3 x week(until levels are \>75 nmol/l; 6-12wks) followed by 6 months maintenance supplementation with 2000 IU Vitamin D3 and up to 1000mg Calcium daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin D2/3 Repletion + AEX
Description: Vitamin D repletion with 50,000 IU of Vitamin D2/3 up to 3 x week(until levels are \>75 nmol/l; 6-12wks) followed by 6 months maintenance supplementation with 2000 IU Vitamin D3 and up to 1000mg Calcium daily plus aerobic exercise training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin D2/3 Repletion + RT
Description: Vitamin D repletion with 50,000 IU of Vitamin D2/3 up to 3 x week(until levels are \>75 nmol/l; 6-12wks) followed by 6 months maintenance supplementation with 2000 IU Vitamin D3 and up to 1000mg Calcium daily plus resistance training
Study: NCT03946943

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Draw
Description: Peripheral blood draws for correlative studies characterizing T-cells in peripheral blood will be performed at three timepoints: 1) pre-treatment, 2) on-treatment on cycle 3 day 1, and 3) off-study.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Specimen Collection
Description: Tumor specimen collection via core needle biopsy for correlative studies characterizing T-cells in tumor tissue will occur at three timepoints: 1) pre-treatment, 2) on-treatment on cycle 3 day 1, and 3) off-study.
Study: NCT01443962

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP
Description: applying PEEP 0 cmH2O during pneumoperitoneum continuously

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ZEEP
Description: applying PEEP 10 cmH2O during pneumoperitoneum continuously
Study: NCT03970720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Description: 10 mg metoclopramide four times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 mg matching placebo capsules four times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 mg matching placebo capsules four times a day
Study: NCT00125931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talwin Nx
Description: Talwin NX 50mg po twice
Study: NCT01941862

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation and Cognitive Bias Modification

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation and Cognitive Bias Modification

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation and Cognitive Bias Modification
Study: NCT02359396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MZRW
Description: MZRWs is composed of Fructus Cannabis (HuoMaRen), Radix et Rhizoma Rhei (DaHuang), Radix Paeoniae Alba (BaiShao), Semen Armeniacae Amarum (KuXingRen), Fructus Aurantii Immaturus (ZhiShi) and Cortex Magnoliae Officinalis (HouPo). All MZRW granules will be prepared by PuraPharm International (H.K.) Limited. The entire manufacturing process, from authenticating the raw materials to the final products, is in strict compliance with the standards of Good Manufactory Practice (GMP) and Chinese Pharmacopoeia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MZRW
Description: MZRWs is composed of Fructus Cannabis (HuoMaRen), Radix et Rhizoma Rhei (DaHuang), Radix Paeoniae Alba (BaiShao), Semen Armeniacae Amarum (KuXingRen), Fructus Aurantii Immaturus (ZhiShi) and Cortex Magnoliae Officinalis (HouPo). All MZRW granules will be prepared by PuraPharm International (H.K.) Limited. The entire manufacturing process, from authenticating the raw materials to the final products, is in strict compliance with the standards of Good Manufactory Practice (GMP) and Chinese Pharmacopoeia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MZRW
Description: MZRWs is composed of Fructus Cannabis (HuoMaRen), Radix et Rhizoma Rhei (DaHuang), Radix Paeoniae Alba (BaiShao), Semen Armeniacae Amarum (KuXingRen), Fructus Aurantii Immaturus (ZhiShi) and Cortex Magnoliae Officinalis (HouPo). All MZRW granules will be prepared by PuraPharm International (H.K.) Limited. The entire manufacturing process, from authenticating the raw materials to the final products, is in strict compliance with the standards of Good Manufactory Practice (GMP) and Chinese Pharmacopoeia.
Study: NCT01739829

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIABECELL (R)
Description: 10,000 IEQ per kg body weight (Total Dose) Administered in two doses: 5,000 IEQ/kg three months apart.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIABECELL (R)
Description: 20,000 IEQ per kg body weight (Total Dose) Administered in two doses: 10,000 IEQ/kg three months apart
Study: NCT04469179

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAB-185
Description: SAB-185 is a purified human immunoglobulin G (hIgG) designed to specifically bind to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) viruses. SAB-185 is purified from the plasma of immunized Tc bovines that were immunized initially (vaccinations 1 and 2) with a plasmid DNA (pDNA) vaccine that expresses wild-type SARS-CoV-2 spike protein, followed by additional immunizations (vaccinations 3 and beyond) with a recombinant spike protein from SARS-CoV-2 produced in insect cells. The purified hIgG is a sterile liquid formulated in 10 mM glutamic acid monosodium salt, 262 mM D-sorbitol, 0.05 mg/mL Tween 80, pH 5.5. The drug product will be administered intravenously and will be diluted in saline per the clinical protocol.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAB-185
Description: SAB-185 is a purified human immunoglobulin G (hIgG) designed to specifically bind to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) viruses. SAB-185 is purified from the plasma of immunized Tc bovines that were immunized initially (vaccinations 1 and 2) with a plasmid DNA (pDNA) vaccine that expresses wild-type SARS-CoV-2 spike protein, followed by additional immunizations (vaccinations 3 and beyond) with a recombinant spike protein from SARS-CoV-2 produced in insect cells. The purified hIgG is a sterile liquid formulated in 10 mM glutamic acid monosodium salt, 262 mM D-sorbitol, 0.05 mg/mL Tween 80, pH 5.5. The drug product will be administered intravenously and will be diluted in saline per the clinical protocol.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAB-185
Description: SAB-185 is a purified human immunoglobulin G (hIgG) designed to specifically bind to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) viruses. SAB-185 is purified from the plasma of immunized Tc bovines that were immunized initially (vaccinations 1 and 2) with a plasmid DNA (pDNA) vaccine that expresses wild-type SARS-CoV-2 spike protein, followed by additional immunizations (vaccinations 3 and beyond) with a recombinant spike protein from SARS-CoV-2 produced in insect cells. The purified hIgG is a sterile liquid formulated in 10 mM glutamic acid monosodium salt, 262 mM D-sorbitol, 0.05 mg/mL Tween 80, pH 5.5. The drug product will be administered intravenously and will be diluted in saline per the clinical protocol.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
Study: NCT02116933

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SVF Enriched Autologous Fat Grafting
Description: Cell assisted lipotransfer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SVF Enriched Autologous Fat Grafting
Description: Cell assisted lipotransfer
Study: NCT04018131

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cimetidine
Description: Antihistamine 2 antagonist
Study: NCT03268031

Intervention type: DIAGNOSTIC_TEST
Intervention: Visual field and OCT tests
Description: Visual field test and OCT are commonly used essential tests to make accurate diagnosis of glaucoma. Algorithms to classify Visual field and OCT tests would both be developed and verified.

Intervention type: DIAGNOSTIC_TEST
Intervention: Visual field and OCT tests
Description: Visual field test and OCT are commonly used essential tests to make accurate diagnosis of glaucoma. Algorithms to classify Visual field and OCT tests would both be developed and verified.
Study: NCT01427868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB80380 maleate salt
Description: 183 mg (150 mg as a free base)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LB80380 free base
Description: 150 mg
Study: NCT01490632

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally
Study: NCT00522327

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: remote simultaneous medical interpreting
Description: remote simultaneous medical interpretation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual and customary
Description: usual and customary interpreting

Intervention type: OTHER
Group type: OTHER
Intervention: ENglish speaking
Description: English speakers
Study: NCT02301780

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Participants who are screened with a high-risk of developing PET will be randomised into one of 2 arms of the trial (on the same day as screening or within 1 week of the screening visit). Randomised participants will be advised to start 150mg of Aspirin/Placebo once per night within 24 hours of randomisation until 36 weeks' gestation or when signs of labour commence.~The maximum duration for aspirin or placebo intake will be 180 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants who are screened with a high-risk of developing PET will be randomised into one of 2 arms of the trial (on the same day as screening or within 1 week of the screening visit). Randomised participants will be advised to start 150mg of Aspirin/Placebo once per night within 24 hours of randomisation until 36 weeks' gestation or when signs of labour commence.~The maximum duration for aspirin or placebo intake will be 180 days.
Study: NCT03804801

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hibiscus Sabdariffa
Description: The extract of the plant Hibiscus Sabdariffa, also known as sour or red tea
Study: NCT04541888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CsA Ophthalmic Gel
Description: The CsA eye gel of 0.3 g: 0.15 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hypromellose Eye Drop
Description: Hypromellose Eye Drops of 10ml：50mg, 3 times daily, 1-2 drop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypromellose Eye Drop
Description: Hypromellose Eye Drops of 10ml：50mg, 3 times daily, 1-2 drop
Study: NCT03612999

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom continuous glucose monitor
Description: Continuous glucose monitors (CGMs) record subjects glucose levels

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit activity tracker
Description: Activity trackers will record subjects' physical activity, heart rate, and sleep.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Subjects record daily activity
Description: Subjects will record their daily activities, either on paper or on a secure texting app.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Subjects record psychological state
Description: Subjects will record their psychological state, either on paper or on a secure texting app.
Study: NCT03705884

Intervention type: OTHER
Group type: OTHER
Intervention: 18F-FDG
Description: Hybrid 18F-FDG PET/MR imaging for observational diagnostic purposes.

Intervention type: OTHER
Group type: OTHER
Intervention: 18F-FDG
Description: Hybrid 18F-FDG PET/MR imaging for observational diagnostic purposes.

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisolone
Description: Oral course of Prednisolone for treatment of sarcoidosis (patient cohort) or as control (healthy volunteer cohort)
Study: NCT04018131

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo drug
Study: NCT02773901

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HS-1000
Study: NCT02673736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX73086
Study: NCT03197480

Intervention type: DRUG
Group type: OTHER
Intervention: Aflibercept Injection [Eylea]
Description: All subjects will receive 4 monthly intravitreal injections of aflibercept
Study: NCT01837264

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magellan®
Study: NCT01999816

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Redesign
Description: Individualized program for lifestyle redesign aimed at decreasing the risk of medically serious pressure ulcers led by licensed occupational therapists trained in the implementation of the lifestyle redesign program
Study: NCT03340597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318
Description: F901318 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318
Description: F901318 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318
Description: F901318 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F901318
Description: F901318 tablet
Study: NCT00425932

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: At Week 24 or any time up to Week 48 if the Patient DAS 28 \> 2.6 patients will be retreated with 1000 mg IV at Day and Day 15.
Study: NCT03014583

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Precision Spectra™ system
Description: Neurostimulation procedures

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Precision Spectra™ system
Description: Neurostimulation procedures

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Precision Spectra™ system
Description: Neurostimulation procedures

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Precision Spectra™ system
Description: Neurostimulation procedures

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Precision Spectra™ system
Description: Neurostimulation procedures

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Precision Spectra™ system
Description: Neurostimulation procedures
Study: NCT02513160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone Dipropionate 640
Description: Beclomethasone Dipropionate 640 mcg BAI
Study: NCT00999479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norethindrone acetate and ethinyl estradiol tablets, USP
Description: Loestrin® 24 Fe provides a dosage regimen consisting of 24 white progestogen-estrogen contraceptive tablets and 4 brown ferrous fumarate (placebo) tablets.~Each white tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol. Each white tablet also contains the following inactive ingredients: acacia, lactose, magnesium stearate, starch, confectioner's sugar, and talc.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ferrous fumarate (placebo) tablets
Description: Loestrin® 24 Fe provides a dosage regimen consisting of 24 white progestogen-estrogen contraceptive tablets and 4 brown ferrous fumarate (placebo) tablets. Each brown tablet contains ferrous fumarate, microcrystalline cellulose, magnesium stearate, povidone, sodium starch glycolate, and compressible sugar. The ferrous fumarate tablets do not serve any therapeutic purpose.
Study: NCT04478279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST101
Description: ST101 will be administered intravenously (IV), initially once per week with a flat dose on the schedule described for each study arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST101
Description: ST101 will be administered intravenously (IV), initially once per week with a flat dose on the schedule described for each study arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST101
Description: ST101 will be administered intravenously (IV), initially once per week with a flat dose on the schedule described for each study arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST101
Description: ST101 will be administered intravenously (IV), initially once per week with a flat dose on the schedule described for each study arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST101
Description: ST101 will be administered intravenously (IV), initially once per week with a flat dose on the schedule described for each study arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST101
Description: ST101 will be administered intravenously (IV), initially once per week with a flat dose on the schedule described for each study arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST101
Description: ST101 will be administered intravenously (IV), initially once per week with a flat dose on the schedule described for each study arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation
Study: NCT01742767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatinum

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatinum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Study: NCT01060163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: A bolus of 10 mg/kg after anesthetic induction over 10 min followed by a maintenance of 10 mg/kg/h for the duration of surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: A bolus of 10 mg/kg after anesthetic induction over 10 min followed by a maintenance of 10 mg/kg/h for the duration of surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: A bolus of 10 mg/kg after anesthetic induction over 10 min followed by a maintenance of 10 mg/kg/h for the duration of surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline served as placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline served as placebo
Study: NCT03705884

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisolone
Description: Oral course of Prednisolone for treatment of sarcoidosis (patient cohort) or as control (healthy volunteer cohort)